SCVI104
SCVIi049-A
General
Cell Line |
|
| hPSCreg name | SCVIi049-A |
| Cite as: | SCVIi049-A (RRID:CVCL_B7SI) |
| Alternative name(s) |
SCVI104
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBRCULi016-A-1 (SCN5A p.R219H-14C-ISO) Donor's gene variants: SCN5A Donor diseases: dilated cardiomyopathy |
| Last update | 9th May 2022 |
| User feedback | |
Provider |
|
| Generator | Stanford Cardiovascular Institute (SCVI) |
External Databases |
|
| BioSamples | SAMEA14322389 |
| Cellosaurus | CVCL_B7SI |
| Wikidata | Q112930366 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA14322388 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | Joseph Wu |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | |
| Approval number | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell line name |
Human Skin fibroblast cells Derived from same source line (potentially other lot and donor, see below):
|
| Source cell type |
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
Other medium:
Base medium: StemMACS
Main protein source: StemMACS brew Serum concentration: % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal
Passage number: 10
Karyotyping method:
Karyo+
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.